NCT03399448: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) |
|
|
| Terminated | 1 | 3 | US | NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing | University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Tmunity Therapeutics | Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | 02/20 | 10/20 | | |
